Triple-negative breast cancer (TNBC), one of the three IHC-defined subtypes routinely assessed in clinical practice, is characterized by the lack of expression of estrogen receptor alpha (ERα) and progesterone receptor (PR), as well as non-amplified levels of human epidermal growth factor receptor 2 (HER-2) in carcinoma cells. This evidence concerns the gene PGR and carcinoma.